In parallel, researchers need to develop biomarkers that predict and monitor CD8+ T-cell responses in real time, and dissect the immunosuppressive networks that sustain tumor “coldness”; and the ultimate goal is to convert prostate cancer into an immunologically “hot” state. Here, CD8A is linked to prostate carcinoma.